X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-11-05 | ADMA | Adma Biologics, Inc. | Grossman Adam S | Pres, CEO | S - Sale+OE | $12.00 | -147,000 | 3,795,160 | -4% | -$1,764,000 | |||||
| M | 2026-11-03 | ETRA | Electra Therapeutics, Inc. | Gordon Carl L | Dir, 10% | P - Purchase | $7.63 | +472,571 | 2,136,979 | +28% | +$3,605,116 | |||||
| M | 2026-11-03 | ETRA | Electra Therapeutics, Inc. | Orbimed Advisors LLC | Dir, 10% | P - Purchase | $7.63 | +472,571 | 2,136,979 | +28% | +$3,605,116 | |||||
2026-11-03 | IPSC | Century Therapeutics, Inc. | Carr Douglas | SVP Finance, Operations | S - Sale | $1.52 | -266 | 502,641 | 0% | -$404 | ||||||
2026-11-03 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $135.40 | -949 | 62,840 | -1% | -$128,496 | ||||||
2026-11-03 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $135.40 | -2,565 | 180,278 | -1% | -$347,306 | ||||||
| D | 2026-11-03 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $135.40 | -4,573 | 558,187 | -1% | -$619,193 | |||||
2026-11-03 | TWST | Twist Bioscience Corp | Werner Robert F. | Chief Accounting Officer | S - Sale | $135.40 | -148 | 42,769 | 0% | -$20,039 | ||||||
2026-11-03 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $135.40 | -1,007 | 105,625 | -1% | -$136,350 | ||||||
2026-11-02 | LYCA | Lycia Therapeutics, Inc. | Venrock Healthcare Capital Partners Iii, L.P. | 10% | P - Purchase | $26.95 | +8,305 | 6,858,542 | 0% | +$223,820 | ||||||
2026-11-03 | RXRX | Recursion Pharmaceuticals, Inc. | Borgeson Blake | Dir | S - Sale | $3.88 | -40,000 | 6,068,287 | -1% | -$155,200 | ||||||
| D | 2026-11-02 | PCVX | Vaxcyte, Inc. | Cowan Elvia | SVP, Finance, CAO | S - Sale+OE | $60.92 | -3,000 | 27,860 | -10% | -$182,753 | |||||
| D | 2026-11-02 | PCVX | Vaxcyte, Inc. | Wassil Jim | EVP, Chief Scientific Ofc, COO | S - Sale+OE | $60.90 | -2,250 | 145,435 | -2% | -$137,024 | |||||
2026-11-02 | MAZE | Maze Therapeutics, Inc. | Coloma Jason V | CEO | S - Sale | $30.25 | -34,501 | 199,866 | -15% | -$1,043,766 | ||||||
2026-11-03 | FATE | Fate Therapeutics Inc | Adawi Kamal | CFO | S - Sale | $2.05 | -6,582 | 93,418 | -7% | -$13,525 | ||||||
| M | 2026-11-02 | VIR | Vir Biotechnology, Inc. | De Verneuil Vanina | EVP, GC, Corp Sec | S - Sale | $11.18 | -3,750 | 110,193 | -3% | -$41,939 | |||||
| D | 2026-11-02 | REPL | Replimune Group, Inc. | Dhingra Kapil | Dir | S - Sale+OE | $19.00 | -21,500 | 21,669 | -50% | -$408,500 | |||||
| DM | 2026-10-30 | ADPT | Adaptive Biotechnologies Corp | Rubinstein Julie | Pres, COO | S - Sale+OE | $26.06 | -35,643 | 377,802 | -9% | -$928,891 | |||||
| DM | 2026-10-30 | BBTX | Bambusa Therapeutics, Inc. | Ra Capital Management, L.P. | Dir, 10% | P - Purchase | $15.79 | +2,953,820 | 1,495,971 | -203% | +$46,639,957 | |||||
2026-11-02 | ARTV | Artiva Biotherapeutics, Inc. | Horan Christopher | Chief Tech Operations Officer | S - Sale | $4.18 | -10,423 | 302,321 | -3% | -$43,580 | ||||||
2026-11-02 | ARTV | Artiva Biotherapeutics, Inc. | Bush Jennifer | COO, CLO, Compliance Officer | S - Sale | $4.18 | -8,439 | 357,720 | -2% | -$35,284 | ||||||
2026-11-02 | ARTV | Artiva Biotherapeutics, Inc. | Banerjee Subhashis | Chief Medical Officer | S - Sale | $4.18 | -1,110 | 168,738 | -1% | -$4,641 | ||||||
2026-11-02 | ARTV | Artiva Biotherapeutics, Inc. | Aslan Fred | CEO | S - Sale | $4.18 | -62,178 | 1,457,428 | -4% | -$259,972 | ||||||
| DM | 2026-10-30 | GILD | Gilead Sciences, Inc. | O'Day Daniel Patrick | COB, CEO | S - Sale+OE | $172.57 | -30,881 | 551,683 | -5% | -$5,329,178 | |||||
2026-10-29 | LENZ | Lenz Therapeutics, Inc. | Ra Capital Management, L.P. | 10% | S - Sale | $3.36 | -2,718,684 | 57,559 | -98% | -$9,134,778 | ||||||
| D | 2026-11-02 | BBTX | Bambusa Therapeutics, Inc. | Salvia Investment Gmbh | 10% | P - Purchase | $16.00 | +375,000 | 9,264,301 | +4% | +$6,000,000 | |||||
| D | 2026-11-02 | BBTX | Bambusa Therapeutics, Inc. | Jeggle Helmut Wolfgang | Dir, 10% | P - Purchase | $16.00 | +375,000 | 9,264,301 | +4% | +$6,000,000 | |||||
| M | 2026-10-28 | LYCA | Lycia Therapeutics, Inc. | Venrock Healthcare Capital Partners Iii, L.P. | 10% | P - Purchase | $25.78 | +25,004 | 6,850,237 | 0% | +$644,711 | |||||
2026-10-28 | IMVT | Immunovant, Inc. | Girao Tiago | CFO | S - Sale | $28.50 | -6,606 | 234,192 | -3% | -$188,271 | ||||||
2026-10-28 | RLAY | Relay Therapeutics, Inc. | Rahmer Peter | See remarks | S - Sale | $18.62 | -753 | 222,904 | 0% | -$14,021 | ||||||
2026-10-28 | RLAY | Relay Therapeutics, Inc. | Bergstrom Donald A | Pres, R, D | S - Sale | $18.62 | -2,252 | 396,878 | -1% | -$41,932 | ||||||
2026-10-28 | RLAY | Relay Therapeutics, Inc. | Catinazzo Thomas | CFO | S - Sale | $18.62 | -1,469 | 103,665 | -1% | -$27,353 | ||||||
| D | 2026-10-29 | MAZE | Maze Therapeutics, Inc. | Dandekar Atul | CSBO | S - Sale+OE | $32.07 | -7,500 | 32,316 | -19% | -$240,532 | |||||
| DM | 2026-10-27 | ADPT | Adaptive Biotechnologies Corp | Rubinstein Julie | Pres, COO | S - Sale+OE | $28.00 | -35,643 | 377,802 | -9% | -$998,097 | |||||
| DE | 2026-10-26 | LONA | Leonabio, Inc. | Portman David J. | 10% | P - Purchase | $0.00 | +3,149,470 | 3,149,470 | New | +$3,149 | |||||
| D | 2026-10-26 | RVMD | Revolution Medicines, Inc. | Mancini Anthony | See Remarks | S - Sale+OE | $186.99 | -2,310 | 39,765 | -5% | -$431,947 | |||||
| M | 2026-10-23 | SRRK | Scholar Rock Holding Corp | Akkaraju Srinivas | Dir | P - Purchase | $41.45 | +289,470 | 7,131,508 | +4% | +$11,999,922 | |||||
| DM | 2026-10-23 | LYCA | Lycia Therapeutics, Inc. | Venrock Healthcare Capital Partners Iii, L.P. | 10% | P - Purchase | $18.41 | +2,045,440 | 6,825,233 | +43% | +$37,653,863 | |||||
2026-10-23 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $134.59 | -2,245 | 182,843 | -1% | -$302,152 | ||||||
| D | 2026-10-23 | PLUR | Pluri Inc. | Manieu Alexandre Weinstein | Dir, 10% | P - Purchase | $1.50 | +833,334 | 2,090,900 | +66% | +$1,250,001 | |||||
| DM | 2026-10-22 | ADPT | Adaptive Biotechnologies Corp | Rubinstein Julie | Pres, COO | S - Sale+OE | $25.18 | -35,643 | 377,802 | -9% | -$897,457 | |||||
| M | 2026-10-22 | ACOG | Alpha Cognition Inc. | Opaleye Management Inc. | 10% | P - Purchase | $8.28 | +32,090 | 3,391,984 | +1% | +$265,820 | |||||
| D | 2026-10-12 | EXOZ | Exozymes Inc. | Perriman Damien Alan | Chief Commercial Officer | S - Sale+OE | $5.21 | -3,729 | 28,692 | -12% | -$19,427 | |||||
2026-10-23 | AIM | Aim Immunotech Inc. | Equels Thomas K | CEO, Pres | P - Purchase | $0.16 | +31,675 | 189,747 | +20% | +$5,068 | ||||||
| D | 2026-10-21 | KOD | Kodiak Sciences Inc. | Borgeson John A. | CFO | S - Sale+OE | $90.01 | -30,000 | 211,930 | -12% | -$2,700,322 | |||||
2026-10-21 | IMVT | Immunovant, Inc. | Stout Jay S | CTO | S - Sale | $28.94 | -2,595 | 198,937 | -1% | -$75,099 | ||||||
2026-10-21 | ALLO | Allogene Therapeutics, Inc. | Parker Geoffrey M. | CFO | S - Sale | $1.34 | -36,342 | 1,045,877 | -3% | -$48,698 | ||||||
2026-10-22 | AIM | Aim Immunotech Inc. | Equels Thomas K | CEO, Pres | P - Purchase | $0.16 | +31,250 | 158,072 | +25% | +$5,094 | ||||||
2026-10-21 | AGMB | Agomab Therapeutics Nv | Epstein David R | Dir | P - Purchase | $8.88 | +10,000 | 25,000 | +67% | +$88,800 | ||||||
| DM | 2026-10-19 | ADPT | Adaptive Biotechnologies Corp | Rubinstein Julie | Pres, COO | S - Sale+OE | $24.66 | -35,643 | 377,802 | -9% | -$879,088 | |||||
| D | 2026-10-19 | DNA | Ginkgo Bioworks Holdings, Inc. | Coen Steven P. | See remarks | S - Sale+OE | $10.14 | -766 | 50,168 | -2% | -$7,770 | |||||
| D | 2026-10-19 | DNA | Ginkgo Bioworks Holdings, Inc. | Canton Barry | 10% | S - Sale+OE | $10.14 | -41,172 | 810,280 | -5% | -$417,608 | |||||
| D | 2026-10-19 | DNA | Ginkgo Bioworks Holdings, Inc. | Shetty Reshma P. | See remarks, 10% | S - Sale+OE | $10.14 | -41,172 | 810,280 | -5% | -$417,608 | |||||
| D | 2026-10-19 | DNA | Ginkgo Bioworks Holdings, Inc. | Kelly Jason R | See remarks | S - Sale+OE | $10.14 | -45,682 | 129,065 | -26% | -$463,353 | |||||
2026-10-20 | MGTX | Meiragtx Holdings Plc | Giroux Richard | CFO, COO | S - Sale | $9.95 | -56,000 | 942,682 | -6% | -$557,200 | ||||||
| M | 2026-10-15 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $0.95 | +500 | 385,385 | 0% | +$475 | |||||
| D | 2026-10-19 | CRSP | Crispr Therapeutics AG | Kulkarni Samarth | CEO | S - Sale+OE | $49.78 | -47,837 | 311,899 | -13% | -$2,381,326 | |||||
| D | 2026-10-16 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | GC | S - Sale+OE | $12.84 | -1,635 | 8,617 | -16% | -$20,993 | |||||
| D | 2026-10-19 | SLDB | Solid Biosciences Inc. | Brooks Gabriel | Chief Medical Officer | S - Sale+OE | $5.62 | -4,374 | 97,241 | -4% | -$24,582 | |||||
| D | 2026-10-16 | IAM | Iambic Therapeutics, Inc. | Rachlin Evan Lockwood | Dir | P - Purchase | $16.00 | +718,750 | 57,754 | -109% | +$11,500,000 | |||||
| M | 2026-10-15 | ACOG | Alpha Cognition Inc. | Opaleye Management Inc. | 10% | P - Purchase | $8.35 | +36,940 | 3,359,894 | +1% | +$308,576 | |||||
| D | 2026-10-15 | CGON | Cg Oncology, Inc. | Post Leonard E | Dir | S - Sale+OE | $62.07 | -1,000 | 0 | -100% | -$62,065 | |||||
2026-10-16 | XFOR | X4 Pharmaceuticals, Inc | Craig Adam R | Exec COB | P - Purchase | $2.58 | +4,600 | 333,251 | +1% | +$11,884 | ||||||
| DM | 2026-10-15 | BEAM | Beam Therapeutics Inc. | Evans John M. | CEO | S - Sale+OE | $23.77 | -50,000 | 1,150,205 | -4% | -$1,188,745 | |||||
| DM | 2026-10-14 | ADPT | Adaptive Biotechnologies Corp | Rubinstein Julie | Pres, COO | S - Sale+OE | $25.18 | -35,643 | 377,802 | -9% | -$897,356 | |||||
| D | 2026-10-14 | CRSP | Crispr Therapeutics AG | George Simeon | Dir | S - Sale+OE | $49.63 | -14,514 | 2,054,249 | -1% | -$720,373 | |||||
2026-10-15 | GILD | Gilead Sciences, Inc. | Dickinson Andrew D | CFO | S - Sale | $156.22 | -3,000 | 161,096 | -2% | -$468,660 | ||||||
2026-10-15 | GILD | Gilead Sciences, Inc. | Mercier Johanna | Chief Comm, Corp Aff Officer | S - Sale | $156.22 | -3,000 | 113,684 | -3% | -$468,660 | ||||||
| DM | 2026-10-14 | MRNA | Moderna, Inc. | Hoge Stephen | Pres | S - Sale+OE | $217.10 | -78,369 | 1,792,614 | -4% | -$17,013,538 | |||||
| D | 2026-10-14 | CRSP | Crispr Therapeutics AG | Kasinger James R. | GC, Secretary | S - Sale+OE | $49.26 | -1,040 | 95,857 | -1% | -$51,230 | |||||
| D | 2026-10-14 | CRSP | Crispr Therapeutics AG | Kulkarni Samarth | CEO | S - Sale+OE | $49.26 | -4,098 | 259,736 | -2% | -$201,867 | |||||
| D | 2026-10-13 | TRXB | Trex Bio, Inc. | Alexandria Venture Investments, LLC | 10% | P - Purchase | $14.00 | +178,571 | 1,346,501 | +15% | +$2,499,994 | |||||
2026-10-14 | INBX | Inhibrx Biosciences, Inc. | Lappe Mark | CEO | P - Purchase | $84.56 | +10,040 | 970,453 | +1% | +$848,977 | ||||||
| D | 2026-10-12 | INKT | Mink Therapeutics, Inc. | Buell Jennifer | CEO | S - Sale+OE | $10.56 | -6,938 | 74,195 | -9% | -$73,265 | |||||
2026-10-09 | OCGN | Ocugen, Inc. | Musunuri Shankar | CEO | S - Sale | $0.95 | -525,991 | 5,049,241 | -9% | -$499,691 | ||||||
| DM | 2026-10-09 | ADPT | Adaptive Biotechnologies Corp | Rubinstein Julie | Pres, COO | S - Sale+OE | $25.81 | -35,643 | 377,802 | -9% | -$919,870 | |||||
| D | 2026-10-08 | TRXB | Trex Bio, Inc. | Svlsf Vi, LLC | 10% | P - Purchase | $14.00 | +92,857 | 3,011,818 | +3% | +$1,299,998 | |||||
2026-10-09 | TWST | Twist Bioscience Corp | Laponis Adam | CFO | S - Sale | $156.31 | -2,462 | 98,114 | -2% | -$384,823 | ||||||
2026-10-07 | IMVT | Immunovant, Inc. | Stout Jay S | CTO | S - Sale | $32.06 | -3,809 | 201,532 | -2% | -$122,117 | ||||||
2026-10-07 | IMVT | Immunovant, Inc. | Van Tuyl Christopher | GC | S - Sale | $32.06 | -1,327 | 175,218 | -1% | -$42,544 | ||||||
2026-10-07 | IMVT | Immunovant, Inc. | Gloria Melanie | COO | S - Sale | $32.06 | -2,241 | 217,060 | -1% | -$71,846 | ||||||
| M | 2026-10-08 | BNTX | Biontech Se | Sahin Ugur | CEO, 10% | S - Sale | $94.07 | -63,209 | 39,218,111 | 0% | -$5,945,855 | |||||
2026-10-08 | AGMB | Agomab Therapeutics Nv | Epstein David R | Dir | P - Purchase | $8.90 | +5,000 | 15,000 | +50% | +$44,500 | ||||||
| DM | 2026-10-06 | HALO | Halozyme Therapeutics, Inc. | Torley Helen | Pres, CEO | S - Sale+OE | $110.18 | -60,000 | 767,780 | -7% | -$6,610,501 | |||||
| DM | 2026-10-06 | ADPT | Adaptive Biotechnologies Corp | Rubinstein Julie | Pres, COO | S - Sale+OE | $26.60 | -35,643 | 377,802 | -9% | -$948,223 | |||||
2026-10-06 | ADPT | Adaptive Biotechnologies Corp | Bobulsky Susan | Chief Commercial Officer, MRD | S - Sale | $30.00 | -6,444 | 389,350 | -2% | -$193,320 | ||||||
| D | 2026-10-06 | CRSP | Crispr Therapeutics AG | Kasinger James R. | GC, Secretary | S - Sale+OE | $60.04 | -1,990 | 94,784 | -2% | -$119,481 | |||||
2026-10-07 | RLAY | Relay Therapeutics, Inc. | Patel Sanjiv | Pres, CEO | S - Sale | $18.10 | -48,199 | 1,358,204 | -3% | -$872,402 | ||||||
2026-10-06 | RLAY | Relay Therapeutics, Inc. | Catinazzo Thomas | CFO | S - Sale | $18.59 | -17,717 | 105,134 | -14% | -$329,322 | ||||||
2026-10-06 | RXRX | Recursion Pharmaceuticals, Inc. | Borgeson Blake | Dir | S - Sale | $4.84 | -50,000 | 6,108,287 | -1% | -$242,000 | ||||||
| D | 2026-10-06 | RXRX | Recursion Pharmaceuticals, Inc. | Hershberg Robert | Dir | S - Sale+OE | $5.00 | -25,000 | 162,156 | -13% | -$125,000 | |||||
2026-10-07 | BNTX | Biontech Se | Sahin Ugur | CEO, 10% | S - Sale | $95.86 | -24,000 | 39,281,320 | 0% | -$2,300,633 | ||||||
2026-10-05 | FDMT | 4D Molecular Therapeutics, Inc. | Kirn David | See Remarks | S - Sale | $12.92 | -58,333 | 709,153 | -8% | -$753,937 | ||||||
2026-10-05 | DNA | Ginkgo Bioworks Holdings, Inc. | Coen Steven P. | See remarks | S - Sale | $15.00 | -2,403 | 49,448 | -5% | -$36,045 | ||||||
| D | 2026-10-05 | PCVX | Vaxcyte, Inc. | Wassil Jim | EVP, Chief Scientific Ofc, COO | S - Sale+OE | $86.74 | -18,000 | 145,435 | -11% | -$1,561,320 | |||||
| D | 2026-10-05 | PCVX | Vaxcyte, Inc. | Cowan Elvia | SVP, Finance, CAO | S - Sale+OE | $86.74 | -19,000 | 27,860 | -41% | -$1,648,060 | |||||
| D | 2026-10-05 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $202.15 | -4,548 | 562,760 | -1% | -$919,374 | |||||
2026-10-06 | ARTV | Artiva Biotherapeutics, Inc. | Aslan Fred | CEO | S - Sale | $7.20 | -23,463 | 1,519,606 | -2% | -$168,880 | ||||||
| M | 2026-10-05 | AGMB | Agomab Therapeutics Nv | Epstein David R | Dir | P - Purchase | $8.64 | +10,000 | 10,000 | New | +$86,350 | |||||
2026-10-06 | AGMB | Agomab Therapeutics Nv | Kemula Pierre Thadee Victor | CFO | P - Purchase | $8.59 | +10,000 | 10,000 | New | +$85,940 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |